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We reviewed conﬁ   rmed cases of pediatric invasive 
meningococcal disease in Tijuana, Mexico, and San Diego 
County, California, USA, during 2005–2008. The overall 
incidence and fatality rate observed in Tijuana were similar to 
those found in the US, and serogroup distribution suggests 
that most cases in Tijuana are vaccine preventable.
I
nvasive meningococcal disease (IMD) is caused by 
Neisseria meningitidis. Speciﬁ  c antibodies against the 
capsule are used to deﬁ  ne the 13 known N. meningitidis 
serogroups (1). In the United States, N. meningitidis is 
a leading cause of bacterial meningitis (2,3). According 
to the provisional Active Bacterial Core Surveillance 
report of the Centers for Disease Control and Prevention, 
1,050 cases of IMD were estimated to occur in 2008, 
with an overall incidence of 0.33/100,000 population 
and mortality rate of 0.03/100,000 population. Higher 
age-speciﬁ  c incidence and proportion of deaths occur in 
children and adolescents (4). In the United States, Active 
Bacterial Core Surveillance data show that serogroups B 
(0.11/100,000), C (0.11/100,000), and Y (0.08/100,000) 
are predominant (5).
IMD is a reportable condition in both the United 
States and Mexico. In 2006, the Mexican National 
Epidemiologic Surveillance System reported 60 cases in 
Mexico (population 105,790,700) for a nationwide rate 
of 0.056/100,000 (6). However, only a limited number 
of epidemiologic descriptions of IMD, primarily from 
outbreaks, are available from Mexico. For example, an 
outbreak of 753 cases was recorded during 1945–1949 in 
San Luis Potosi. Most cases were among infants and young 
children; serogroup data were not available (7).
Although physicians in Mexico at the US–Mexico 
border areas often encounter patients with symptoms 
highly compatible with IMD, diagnosis is not routinely 
culture-conﬁ   rmed; this likely leads to underreporting. 
Serogroup-speciﬁ  c data on IMD are also lacking elsewhere 
throughout Mexico. The goals of our study were to compare 
hospital-based estimates of IMD in children and serogroup 
distribution at Tijuana General Hospital (TGH), Mexico, 
with a catchment population of nearly 200,000 children 
<17 years, to reported IMD cases in children in San Diego 
County (SDC), with a population of 723,600 children <17 
years. (All demographic and serogroup data are listed in 
the Table.) This border is the most traversed international 
frontier in the world. We hypothesized that rates of IMD 
are underreported at TGH and that serogroup distribution is 
similar on both sides of the US–Mexico border.
The Study
During October 1, 2005–May 31, 2008, active 
surveillance for IMD was initiated at TGH among children 
<17 years of age. Blood or cerebrospinal ﬂ  uid specimens, or 
both, were collected from all patients with suspected sepsis, 
meningitis, or purpura fulminans. Data on all pediatric IMD 
reported to the SDC Health and Human Services Agency 
through electronic laboratory notiﬁ  cation or from infection 
control practitioners were retrospectively analyzed during 
the same period. Inclusion criteria as follows: per Centers 
for Disease Control and Prevention guidelines (8), we 
included only conﬁ   rmed cases with sterile-site (blood/
cerebrospinal  ﬂ   uid) isolation of N. meningitidis. At the 
SDC Public Health Laboratory, N. meningitidis isolates 
were identiﬁ  ed by using API NH (bioMérieux, La Bolme-
les-Grottes, France)  and serogrouped by standard slide 
agglutination methods. At TGH, isolates were serogrouped 
by standard latex well agglutination methods using 
Pastorex Meningitis kit (Alere Ltd, Stockport, UK). Six 
case-patients from TGH and 7 from SDC with purpura 
fulminans, disseminated intravascular coagulation, or both, 
lacked culture-proven N. meningitidis infection and were 
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Clinical, microbiologic, and demographic data from 
TGH and SDC were analyzed by using STATA, Version 
9.2 (StataCorp, LP, College Station, TX, USA). Pearson χ2 
and Fisher exact tests were performed; p values <0.05 were 
deﬁ  ned as signiﬁ  cant.
During the study period, a total of 29 pediatric cases of 
IMD were diagnosed, 16 at TGH (an estimated 3.08 annual 
cases/100,000 children <17 years) and 13 in SDC (0.69 
annual cases/100,000 children <17 years). Children <5 years 
accounted for most IMD cases at both sites: 9 cases at TGH, 
and 10 in SDC (p = 0.24) (Figure 1). Of the 29 case-patients, 
11 children were 1–4 years of age, and 8 were infants <1 year 
of age. Children <1 year of age accounted for 2 cases at TGH 
and 6 cases in SDC (p<0.05), with most infections in SDC 
caused by serogroup B. A slight male predominance (55.2%) 
was observed on both sides of the border, and 65.5% were 
diagnosed during November–February.
Overall, serogroup C was most commonly identiﬁ  ed 
among the 29 cases (41.4%), followed by B (34.5%) and 
Y (10.3%); another 13.8% of cases were not serogrouped 
(2 cases each at TGH and SDC). A signiﬁ  cant difference 
in serogroup was observed by site: serogroup C was most 
commonly identiﬁ   ed at TGH (62.5%), whereas sero-
group B was most common in SDC (61.5%) (Figure 2) 
(p = 0.005).
Of the 29 IMD case-patients from TGH and SDC, 5 
children died, including 3 from TGH and 2 in SDC. Four 
of those who died were <5 years of age, and 1 child was 15 
years of age. One fatal infection was known to be potentially 
vaccine preventable (caused by serogroup C), but the 
organisms in the other 4 deaths were not serogrouped.
Conclusions 
Documented reports of conﬁ   rmed IMD in Mexico 
are rare (6), resulting in an assumption that incidence 
is extremely low. However, other infectious diseases, 
including tuberculosis, HIV/AIDS, and hepatitis A, B, 
and C, are common in this border region and often occur 
at higher rates than elsewhere in the United States (9) 
This surveillance project describes active hospital-based 
surveillance and serogroup distribution of IMD in children 
on both sides of the US–Mexico border. The age and 
serogroup distribution differed greatly between sites, with 
SDC demonstrating more infant cases and serogroup B, 
while TGH demonstrated more child and adolescent cases 
and serogroups C and Y.
This study suggests that rates of IMD at TGH, and 
presumably Tijuana and elsewhere in Mexico, may be 
substantially higher than reported. During the study period, 
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Figure 1. Cases of invasive meningococcal disease, by case-patient 
age group, Tijuana General Hospital (TGH), Tijuana, Mexico, and 
San Diego County (SDC), California, USA, October 1, 2005–May 
31, 2008. 
Table. Characteristics of pediatric case-patients who had 
invasive meningococcal disease, Tijuana, Mexico, and San 
Diego County, California, USA, October 1, 2005–May 31, 2008* 
Characteristics
No. (%) patients 
Tijuana,
n = 16 
San Diego 
County, n = 13 
Age, y 
  <1  2 (12.5)  6 (46.2) 
  1–4  7 (43.8)  4 (30.8) 
  5–11  4 (25.0)  2 (15.4) 
  12–16  3 (18.8)  1 (7.7) 
Male sex  8 (50.0)  9 (69.2) 
Race/ethnicity
 Non-Hispanic  white  0 6  (46.2) 
  Hispanic  16 (100)  3 (23.1) 
  Non-Hispanic black  0 2 (15.4) 
 Asian  0 0
 Pacific  Islander  0 0
 Other/unknown  0 2  (15.4) 
Month of onset 
  November–February  12 (75.0)  7 (53.8) 
  March–June  2 (25.0)  4 (30.8) 
  July–October  2 (25.0)  2 (15.4) 
Serogroup 
 A  0 0
  B  2 (12.5)  8 (61.5) 
  C  10 (62.5)  2 (15.4) 
  Y  2 (12.5)  1 (7.7) 
 W135  0 0
 Not  typeable  0 0
  Not typed  2 (12.5)  2 (15.4) 
Case-fatality rate  3 (18.8)  2 (15.4) 
*Tijuana cases from hospital-based estimates and serogroup distribution 
at Tijuana General Hospital. San Diego County cases taken from those 
reported to the San Diego County Health and Human Services Agency 
through electronic laboratory notification or from infection control 
practitioners. Invasive Meningococcal Disease, US–Mexico Border
vaccine-preventable serogroups were more common in 
TGH than in SDC. This ﬁ  nding has potential implications 
for immunization with the meningococcal vaccines 
containing serogroups C and Y in Mexico. In the United 
States, the quadrivalent conjugated meningococcal vaccine 
is recommended for all persons 11–18 years of age and is 
indicated for persons 2–55 years of age who are at increased 
risk for IMD (10,11). This vaccine might have beneﬁ  ts in 
Tijuana in terms of carriage of the bacteria and reduction 
in serogroup-speciﬁ   c IMD incidence, effects which 
have been demonstrated elsewhere (12,13). Widespread 
meningococcal vaccination has not yet been introduced in 
Tijuana or elsewhere in Mexico, although the monovalent 
meningococcal C conjugate vaccine has been licensed in 
Mexico. This study suggests that a substantial number of 
IMD cases might have been prevented with quadrivalent 
conjugated meningococcal vaccine (75%) or monovalent 
serogroup C vaccine (63%). A recent study has shown 
that monovalent serogroup C vaccination administered to 
children <2 years of age could be effective in preventing 
IMD among infants (14).
This investigation was limited in several aspects, 
however. Tijuana serogroup data was only available for 
TGH (the city’s indigent tertiary care referral center), 
which likely led to an underestimation of the number of 
pediatric IMD cases. Even though data were reviewed for 
nearly 3 years, the relatively small geographic area resulted 
in a small sample size, which limits generalizations.
IMD is likely to occur at a higher rate than previously 
reported in Tijuana. The overall incidence and fatality 
rate observed for TGH cases were similar to rates in the 
United States, and serogroup distribution at TGH indicates 
that most IMD cases in Tijuana are vaccine preventable. 
Establishment of a binational IMD surveillance system 
could provide substantial beneﬁ  t in improving IMD control 
potentially leading to vaccination strategies in Mexico’s 
northern border region, and perhaps elsewhere. Further 
IMD surveillance studies including binational systems are 
needed to better deﬁ  ne the epidemiology of IMD in the 
northern border and other regions of Mexico and determine 
appropriate vaccination policies.
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Figure 2. Cases of invasive meningococcal disease, by serogroup, 
Tijuana General Hospital (TGH), Tijuana, Mexico, and San Diego 
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